Summary & Overview
Percutaneous and Other Intracardiac Procedures with MCC: Inpatient Reimbursement Overview
DRG 273 encompasses percutaneous and other intracardiac procedures accompanied by a Major Complication or Comorbidity, representing high-acuity catheter-based or intracardiac interventions. This classification matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity elevates the Diagnosis-Related Group assignment and typically increases Medicare payment to reflect greater resource intensity.
DRG 273 Overview
DRG 273 covers hospital admissions for percutaneous and other intracardiac procedures that involve a Major Complication or Comorbidity, typically including complex catheter-based interventions, device implantations, or intracardiac repairs with significant additional diagnoses. These cases often require advanced cardiovascular medicine, interventional cardiology, and sometimes cardiothoracic surgical support. The presence of a Major Complication or Comorbidity increases resource use and influences Medicare inpatient payment classification under the Diagnosis-Related Group system. Accurate coding of principal procedures and accompanying major complications is central to appropriate Medicare reimbursement.
Clinical Trials
- Acute periprocedural intervention trials: studies that evaluate novel percutaneous intracardiac techniques, adjunctive devices, or procedural strategies in patients undergoing high-risk catheter-based intracardiac procedures with major complications (for example patients with hemodynamic instability, life‑threatening arrhythmias, or procedural bleeding). These trials focus on immediate procedural safety, complication mitigation, and short-term clinical endpoints (mortality, need for emergency surgery, length of ICU stay). Results inform operators and hospital administrators about interventions that can reduce in-hospital morbidity, resource use, and cost for patients captured in this DRG.
- Comparative effectiveness research of alternative percutaneous approaches in complex comorbidity cohorts: head‑to‑head or registry‑based studies comparing different percutaneous techniques or device platforms in populations with significant comorbidities (advanced age, renal dysfunction, heart failure, prior cardiac surgery) who develop major complications. These studies evaluate outcomes such as reintervention rates, in‑hospital complications, and disposition at discharge to identify which approaches perform better in higher‑risk subgroups. Findings are relevant to clinicians and payers by guiding selection of technically appropriate, cost‑effective strategies for patients likely to generate higher resource use under this DRG.
- Post‑discharge outcomes and utilization studies for patients surviving intracardiac percutaneous procedures with major complications: observational cohort studies tracking readmissions, post‑acute care needs, long‑term functional status, and healthcare utilization among survivors of complicated percutaneous intracardiac procedures. Research examines predictors of readmission, effectiveness of transitional care models, and the impact of complications on downstream costs and quality metrics. This evidence helps hospitals, case managers, and payers plan discharge pathways and bundled payment strategies to improve outcomes and control post‑discharge expenditures for this high‑acuity DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.